<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985438</url>
  </required_header>
  <id_info>
    <org_study_id>SKMCHRC-IRB-13-15</org_study_id>
    <nct_id>NCT01985438</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Two Modalities of Prophylactic Nutritional Support During Treatment for Head and Neck Cancer</brief_title>
  <acronym>PRONUS</acronym>
  <official_title>Prophylactic Nutritional Support During Treatment for Head and Neck Cancer: A Single-Center, Open-label, Prospective, Randomized, Controlled Trial Comparing Feeding With Percutaneous Endoscopic Gastrostomy Tubes and Nasogastric Tubes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To compare the effect of prophylactic enteral feeding tube placement (either percutaneous
      endoscopic gastrostomy (PEG) tube or nasogastric (NG) tube) in patients undergoing treatment
      for head and neck cancer (HNC) on nutritional status, quality of life, mental and emotional
      health, rates of clinical complications, and cost of care.

      Study Design:

      Prospective randomized controlled trial with 2 arms and equal allocation ratio

      Study Objectives:

        1. The primary objective is to assess, among HNC patients randomized to receive either
           prophylactic PEG tube or NG tube for enteral support and who are undergoing
           chemo-radiation at SKMCH&amp;RC, the change from baseline in nutritional status at the end
           of 24 weeks after treatment initiation.

        2. The secondary objectives are to assess, among HNC patients randomized to receive either
           prophylactic PEG tube or NG tube for enteral support and who are undergoing
           chemo-radiation at SKMCH&amp;RC, the change from baseline in nutritional status at the end
           of 12 weeks; the rates of complications; quality of life including symptoms of
           depression and anxiety; and cost of care (all related to enteral feeding tube placement
           only) at baseline and at the end of 12 weeks and 24 weeks after treatment initiation.

      Patients and methods:

      Eligible patients will be enrolled consecutively from the gastroenterology outpatient clinics
      at Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH&amp;RC), Lahore and
      randomly assigned to receive either PEG tube or NG tube placement prior to commencement of
      treatment. Patients will receive counseling from a trained nutritionist regarding adequate
      nutrition during treatment and enteral feeding tube care. Detailed information regarding
      demographics, cancer location, type and staging, clinical status, nutritional status, quality
      of life, mental and emotional health, and cost of care will be obtained at baseline (time at
      which cancer treatment is initiated) and on 21st day (3 weeks), 42nd day (6 weeks), 84th day
      (12 weeks) and 168th day (24 weeks) after initiating chemoradiation. The primary endpoint
      will be to compare the nutritional status between the two treatment groups on an
      intent-to-treat basis on 168th day (24 weeks) after initiating chemoradiation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional Status</measure>
    <time_frame>change from baseline nutritional status at 24 weeks after starting treatment</time_frame>
    <description>Nutritional status will be assessed using three methods: (1) Patient-Generated Subjective Global Assessment (PG-SGA) tool, (2) anthropometric data, and (3) biochemical data. Biochemical assessment will be done by measuring serum albumin and electrolytes and kidney function tests. Primary outcome will be analyzed at aggregate level and after stratifying by age, sex, location of tumor, disease severity, and grade of dysphagia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life + Mental/Emotional health</measure>
    <time_frame>change from baseline quality of life &amp; mental/emotional health scores at 12 and 24 weeks</time_frame>
    <description>The quality of life will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) version 3.0. and Functional Assessment of Cancer Therapy Head and Neck (FACT H&amp;N) version 4. Patients will also be assessed for their mental and emotional health. For this purpose, Hospital Anxiety and Depression Scale (HADS) will be used. All of these questionnaires are available in Urdu.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Data on cost of care associated with nutritional support will be assessed from the hospital's and patient's perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complications</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Rate of minor and major clinical complications related to placement of PEG or NG tube will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>change in nutritional status from baseline at 12 weeks after starting treatment</time_frame>
    <description>Nutritional status will be assessed using three methods: (1) Patient-Generated Subjective Global Assessment (PG-SGA) tool, (2) anthropometric data, and (3) biochemical data. Biochemical assessment will be done by measuring serum albumin and electrolytes and kidney function tests. All secondary outcomes will be analyzed at aggregate level and after stratifying by age, sex, location of tumor, disease severity, and grade of dysphagia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>percutaneous endoscopic gastrostomy tube</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasogastric tube</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous endoscopic gastrostomy tube placement</intervention_name>
    <description>A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.</description>
    <arm_group_label>percutaneous endoscopic gastrostomy tube</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nasogastric tube placement</intervention_name>
    <description>All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.</description>
    <arm_group_label>nasogastric tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All treatment-na√Øve patients presenting to the Head and Neck outpatient Clinic at
             Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore AND accepted into
             the system for treatment of a primary malignant neoplasm of head and neck (neoplasms
             of lip; oral cavity; pharynx; and larynx [see appendix for detailed definition and
             corresponding International Classification of Diseases 9th Revision Clinical
             Modification (ICD-9-CM) codes] AND referred to the Gastroenterology (GI) service for
             percutaneous endoscopic gastrostomy tube placement or nasogastric tube placement

          -  18 years or older

        Exclusion Criteria:

          -  Patients who have already received treatment for the neoplasm of head and neck at a
             center other than SKMCH&amp;RC.

          -  Patients with recurrence following earlier treatment for cancer of the head and neck
             region.

          -  Patients presenting with neoplasms of nasal cavities, middle ear and accessory
             sinuses; skin of head, neck and face; neoplasms of eye; and neoplasms of brain.

          -  Patients with contraindications to PEG tube or NG tube placement.

          -  Patients with moderate to severe mental or physical disabilities because such
             disabilities will make it impossible to assess functional status deterioration related
             to the disease or its treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Aasim Yusuf, MBBS, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaukat Khanum Memorial Cancer Hospital and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed Zafar, MBBS, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaukat Khanum Memorial Cancer Hospital and Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Waleed Zafar, MBBS, ScD</last_name>
    <phone>+92-42-3590-5000</phone>
    <phone_ext>4245</phone_ext>
    <email>waleedz@skm.org.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M. Aasim Yusuf, MBBS, FRCP</last_name>
    <phone>+92-42-3590-5000</phone>
    <phone_ext>4002</phone_ext>
    <email>aasim@skm.org.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaukat Khanum Memorial Cancer Hospital and Research Center</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waleed Zafar, MBBS, ScD</last_name>
      <phone>+92 42 35905000</phone>
      <phone_ext>4245</phone_ext>
      <email>waleedz@skm.org.pk</email>
    </contact>
    <investigator>
      <last_name>M. Aasim Yusuf, MBBS, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waleed Zafar, MBBS, ScD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arif Jamshed, MBBS, FRCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Qayyum Khan, MBBS, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Syed R Hussain, MBBS, FDSRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Faisal Zeb, MBBS, MRCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hala Mansoor, MBBS, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Adnan Masood, MBBS, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Nutritional Support</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Percutaneous Endoscopic Gastrostomy tube</keyword>
  <keyword>Nasogastric tube</keyword>
  <keyword>Radiation Effects</keyword>
  <keyword>Pakistan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

